PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Revenue decline while CRVO shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
-100.00%
Cost reduction while CRVO shows 381.57% growth. Joel Greenblatt would examine competitive advantage.
100.00%
Positive growth while CRVO shows decline. John Neff would investigate competitive advantages.
100.00%
Margin change of 100.00% while CRVO shows flat margins. Bruce Berkowitz would examine quality advantage.
7.04%
R&D growth while CRVO reduces spending. John Neff would investigate strategic advantage.
-5.63%
G&A reduction while CRVO shows 79.33% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.59%
Operating expenses growth above 1.5x CRVO's 0.41%. Michael Burry would check for inefficiency.
2.59%
Total costs growth above 1.5x CRVO's 0.41%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
13.04%
D&A growth less than half of CRVO's 51.93%. David Dodd would verify if efficiency is sustainable.
-2.44%
EBITDA decline while CRVO shows 100.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-2.59%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-15.06%
Other expenses reduction while CRVO shows 0.60% growth. Joel Greenblatt would examine advantage.
-3.66%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense growth while CRVO reduces burden. John Neff would investigate differences.
-10.34%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-10.26%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-10.26%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
0.08%
Share count reduction below 50% of CRVO's 0.02%. Michael Burry would check for concerns.
0.08%
Diluted share reduction below 50% of CRVO's 0.02%. Michael Burry would check for concerns.